<DOC>
	<DOCNO>NCT00012454</DOCNO>
	<brief_summary>This study test safety effectiveness protein call E-selectin , give nasal spray , prevent formation blood clot cause stroke . In animal study , animal receive E-selectin nose regular schedule almost stroke compare receive . Patients age 45 stroke transient ischemic attack ( TIA ) within 1 4 month study may eligible participate . Candidates screen review past medical record neurologic medical evaluation may include magnetic resonance imaging ( MRI ) brain , ultrasound magnetic resonance angiography ( type MRI ) carotid artery ( artery neck supply blood brain ) , echocardiography ( ultrasound test heart ) , electrocardiography ( EKG ) blood test . Participants blood urine test assign one four treatment group . Patients group spray small amount fluid nose accord follow schedule : 5 dos every day 10-days , follow 3 week another 5 dos every day 10-days , follow 3 week final series 5 dos every day 10 day . The spray patient group contain follow : - Group 1 - fluid low dose E-selectin - Group 2 - fluid medium dose E-selectin - Group 3 - fluid high dose E-selectin - Group 4 - fluid E-selectin Patients see follow-up visit 1 month 3 month start E-selectin therapy . The visit include neurologic examination blood urine test . Patients contact phone , fax e-mail 1- 3-month visit .</brief_summary>
	<brief_title>E-Selectin Nasal Spray Prevent Stroke Recurrence</brief_title>
	<detailed_description>In United States , stroke third leading cause death lead cause disability . Despite success recent clinical trial antithrombotic drug secondary prevention stroke , annually 10 % patient recent cerebrovascular accident recurrent stroke . The development new treatment strategy secondary prevention stroke important issue modern medicine . There increase evidence inflammation sit endothelial activation play important role pathogenesis stroke . Control molecular inflammation sit endothelial activation achieve induction mucosal tolerance . The induction mucosal tolerance repeat , low-dose , intranasal administration antigen cause shift immune response proinflammatory T ( H ) 1 type anti-inflammatory T ( H ) 2 type site inflammation . E-selectin adhesion molecule express activated endothelium response proinflammatory cytokine . The major goal propose study test whether repeat administration low-dose , intranasal E-selectin induce mucosal tolerance compound cause shift immune response T ( H ) 1 T ( H ) 2 type patient recent stroke TIA , secondly evaluate safety tolerability strategy secondary prevention stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemic Attack , Transient</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients recent ( great 30 less 120 day ) stroke TIA age 45 year eligible current study . Patients must least one antithrombotic medication ( coumadin , aspirin , ticlopidine , clopidogrel , aspirin+dypyridamole ) . Patients allow cholesterol lowering ( simvastatin , pravastatin , atrovastatin ) , antihypertensive ( beta blocker , ACE inhibitor , Ca+ channel blocker , diuretic ) , antidiabetic , nonsteroidal antiinflammatory medication . Patients treat tPA acute phase stroke eligible trial . Males females childbearing potential must adequate form birth control . All patient ( recently ) brain ( CT MRI ) , neurovascular ( ultrasound MRA ) , cardiac ( transthoracic echocardiography ) imaging , well EKG , fast blood surgar , lipid profile , serum homocysteine coagulogram . EXCLUSION CRITERIA : Age le 45 year . Intracranial extracranial dissection , Moya Moya disease , vasculitis , radiationinduced vasculopathy , fibromuscular displasia , venous thrombosis . Immunosuppressive medication include : prednisone , cyclophosphmide , cyclosporine , methotrexate , azathioprine , mycophenolate mofetil , antiCD3 moab ( Othoclone OKT3 ) , takrolimus ( FK506 ) , sirolimus , antiIL2r moab ( simulect , zenapax ) , thymoglobulin , thalidomide . Known autoimmune disease ( RA , LE , MS , Myasthenia Gravis , etc , ) . Cancer lymphoproliferative disease . Thrombocytopenia ( platelet le 100,000 ) . HIV known immunodeficiency . Recent major surgery ( within one month ) . Systemic infection , severe focal infection . Alcohol substance abuse . Dementia psychiatric problem ( determine examination , minimental status test consent interview ) prevent patient provide informed consent follow outpatient program reliably . A severe neurological deficit render patient incapable living independently . Pregnancy . Chronic rhinopathy . Chronic sinusitis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Transforming Growth Factor-Beta</keyword>
	<keyword>Stroke</keyword>
	<keyword>Prevention</keyword>
	<keyword>Mucosal Tolerance</keyword>
	<keyword>E-selectin</keyword>
</DOC>